Indications of Butasiv 50 mg
Butasiv 50 mg is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Butasiv 50 mg is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in the acute cough of any ... Read moreButasiv 50 mg is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Butasiv 50 mg is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in the acute cough of any etiology, whooping cough and cough due to acute lower respiratory tract infections (tracheitis, laryngitis, bronchitis) etc.
Theropeutic Class
Cough suppressant
Pharmacology
Butasiv 50 mg belongs to the anti-cough medicines of central action. It exerts expectorant, moderate bronchodilating and anti-inflammatory action. Butasiv 50 mg also increases the spirometery indexes and blood oxygenation. It is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. The active metabolites of Butasiv 50 mg have also antitussive action.
Dosage & Administration of Butasiv 50 mg
Tablet:
Adult: 2-3 tablets daily at 8 to 12 hours intervals,
Adolescents over 12 years old: 1-2 tablets daily.
Syrup:
Children (3-6 years): 5 ml 3 times daily,
Children (6-12 years): 10 ml 3 times daily,
Adolescent: 15 ml 3 times daily,
Adult: 15 ml 4 times daily.
Pediatric Drops:
Children (1-3 years): 0.75 ml 4 times daily,
Children (2 months-1 year): 0.50 ml 4 times daily.
Dosage of Butasiv 50 mg
Use in adult:
Butasiv 50 mg 50 mg tablet: 2-3 tablets daily.
Butasiv 50 mg syrup: 15 ml 4 times daily.
Use in children & adolescents:Butasiv 50 mg 50 mg tablet:
Adolescent over 12 years old: 1-2 tablets daily.
Butasiv 50 mg syrup:
Children (3-6 yrs): 5 ml 3 times daily.
Children (6-12 yrs): 10 ml 3 times daily.
Adolescent: 15 ml 3 times daily.
Butasiv 50 mg pediatric drops:
Children ( 2 months- 1 yrs): 0.50 ml 4 times daily.
Children (1-3 yrs): 0.75 ml 4 times daily.
Interaction of Butasiv 50 mg
Concomitant use with expectorants should be avoided.
Contraindications
Hypersensitivity to the active ingredient.
Side Effects of Butasiv 50 mg
Tolerance of Butasiv 50 mg is good.Adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal.
Pregnancy & Lactation
Butasiv 50 mg should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Butasiv 50 mg administration during breast feeding should be carefully weighed against the risks.
Precautions & Warnings
Butasiv 50 mg suppresses the cough reflex and therefore the concomitant use with expectorants should be avoided, since it may lead to mucus retention in the airways, which increases the risk of bronchospasm and respiratory infections. If the cough persists for more than 7 days (more than 3 days in children younger than12 years of age) doctor must be consulted.
Overdose Effects of Butasiv 50 mg
Accidental overdose with Butasiv 50 mg can cause the following symptoms: drowsiness, nausea, vomiting, diarrhoea, loss of balance and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.
Storage Conditions
Keep away from light and moisture, store below 30°C. Keep all the medicines out of the reach of children.
Drug Classes
Cough suppressant
Mode Of Action
Butasiv 50 mg acts directly on the brain's cough center to suppress cough. Butasiv 50 mg is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. Butasiv 50 mg is rapidly and completely absorbed after oral administration. Maximum concentration is reached within 9 hours with the sustained-release tablet. This is extremely protein-bound and plasma elimination half-life is about 13 hours. The active metabolites of Butasiv 50 mg have also antitussive action.
Pregnancy
Butasiv 50 mg should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Butasiv 50 mg administration during breast feeding should be carefully weighed against the risks.